About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Georgia | 14,426 Studies Near You | Clareo Health

Clinical Trials LocationsGeorgia

Clinical Trials in Georgia

Discover 14,426 clinical trials near Georgia. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 4541-4560 of 14,426 trials

RECRUITINGNA29 miles

Hyrax Vs. Invisalign Palatal Expander Clinical Study

NCT06662279

The purpose of this study is to compare expansion result and the overall experience between the Invisalign Palatal Expander and the Hyrax expander.

MalocclusionsNarrow MaxillaNarrow Maxillary Arch+1 more

Align Technology, Inc.36 participantsStarted Oct 2024

Laguna Hills, California, United States • Warner Robins, Georgia, United States • Naperville, Illinois, United States +1 more locations

COMPLETEDPhase 363 miles

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

NCT03440385

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

Celgene606 participantsStarted Mar 2018

Scottsdale, Arizona, United States • La Jolla, California, United States • Lancaster, California, United States +365 more locations

Find Trials by Condition in Georgia

Breast Cancerin Georgia Lung Cancerin Georgia Prostate Cancerin Georgia Colorectal Cancerin Georgia Melanomain Georgia Leukemiain Georgia Lymphomain Georgia Pancreatic Cancerin Georgia Ovarian Cancerin Georgia Brain Cancerin Georgia Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 265 miles

Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer

NCT02632045

This is a randomized trial for patients with metastatic hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have progressed on an aromatase inhibitor plus a CDK4/6 inhibitor (either palbociclib or ribociclib) to either fulvestrant alone or fulvestrant with ribociclib (LEE-011). The purpose of the trial is to determine whether there is continued benefit for patients to remain on a CDK4/6 inhibitor at the time of switching anti-estrogen therapy. As ribociclib and palbociclib have a similar toxicity and drug profile and mechanism of action, the investigators feel that it is appropriate for patients to receive either drug with an aromatase inhibitor prior to randomization.

Metastatic Breast CancerBreast Carcinoma

Melissa K Accordino169 participantsStarted Mar 2016

Birmingham, Alabama, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +10 more locations

COMPLETED65 miles

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

NCT04378153

Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating CF, it is still largely unknown whether or not other chronic therapies can be safely stopped. The SIMPLIFY study is being done to test whether or not it is safe to stop taking inhaled hypertonic saline or Pulmozyme® (dornase alfa) in those people that are also taking Trikafta™. Trikafta (elexacaftor/tezacaftor/ivacaftor) is a combination CFTR modulator therapy that was approved by the Food and Drug Administration for people with CF who have at least one F508del mutation. The three drugs that make up Trikafta work together to allow many more chloride ions to move into and out of the cells, improving the balance of salt and water in the lungs. These changes result in better clearance of mucus from the lungs and improvements in lung function. Inhaled hypertonic saline and Pulmozyme (dornase alfa) also improve clearance of mucus from the lungs to support lung function and have been available to people with CF for many years. Both therapies are considered to be relatively burdensome and it is not known whether either therapy can improve or maintain lung function above what is already gained through Trikafta use. The goal of the SIMPLIFY study is to get information about whether or not it is safe to stop either inhaled hypertonic saline or Pulmozyme (dornase alfa) by testing if there is a change in lung function in subjects with cystic fibrosis (CF) who are assigned to stop their chronic medication (either hypertonic saline or Pulmozyme) as compared to those who are assigned to keep taking their medication while continuing to take Trikafta.

Cystic Fibrosis

Nicole Hamblett987 participantsStarted Aug 2020

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Tucson, Arizona, United States +77 more locations

Active Not RecruitingNA65 miles

NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study

NCT03929913

This research protocol tests a new technique and devices that we have developed to treat functional mitral valve regurgitation, called transcatheter mitral valve cerclage annuloplasty, otherwise known as "cerclage". Functional mitral valve regurgitation is a condition caused by damaged heart muscle involving the left ventricle which results in mitral valve leakage. This leakage causes heart failure (breathlessness and lack of energy especially when walking or exercising, and hospital admissions for fluid buildup). This is an early feasibility study (EFS) evaluation of special devices, permanently implanted in the heart, to perform mitral cerclage annuloplasty. Mitral cerclage annuloplasty is a catheter procedure performed under X-ray and ultrasound guidance without surgery. The cerclage devices compress the mitral valve like a purse-string. The cerclage device has a special feature that prevents a coronary artery from getting squeezed as part of this purse-string. The protocol has been changed to allow patients who have mitral valve regurgitation despite prior Mitra-Clip treatment, and to allow patients who have symptomatic heart failure with mild mitral regurgitation.

Functional Mitral Regurgitation

National Heart, Lung, and Blood Institute (NHLBI)19 participantsStarted May 2019

Washington D.C., District of Columbia, United States • Atlanta, Georgia, United States • Roanoke, Virginia, United States

Active Not RecruitingPhase 265 miles

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

NCT06119217

This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in subjects with metastatic PDAC who did not have prior treatment for metastatic disease and are eligible to receive gemcitabine and nab-paclitaxel chemotherapy as SOC.

Pancreatic Cancer

Trishula Therapeutics, Inc.194 participantsStarted Mar 2024

Tucson, Arizona, United States • Hot Springs, Arkansas, United States • Bakersfield, California, United States +61 more locations

TERMINATED65 miles

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke

NCT05421533

The GARDENIA registry will collect real-world clinical data on the anticoagulant strategies in patients with AF at elevated risk of stroke but also elevated risk of bleeding.

Atrial Fibrillation

Anthos Therapeutics, Inc.705 participantsStarted Sep 2022

Fullerton, California, United States • Boca Raton, Florida, United States • Homestead, Florida, United States +93 more locations

COMPLETEDPhase 3142 miles

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

NCT04795531

This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin degludec taken daily. Participants will get their study medicine in an injection pen. Participants will get a pen for weekly injection and one for daily injection. One will be icodec or degludec and the other will be dummy medicine. The treatment participants get is decided by chance. Participants and the study staff will not know which active medicine they get. The insulin is injected with a needle in a skin fold in the thigh. The study could last for about 8 months. Participants will have 13 clinic visits and 17 phone calls with the study doctor. At 8 clinic visits participants will have blood samples taken. At 4 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

Diabetes Mellitus, Type 2

Novo Nordisk A/S588 participantsStarted Mar 2021

Guntersville, Alabama, United States • Buena Park, California, United States • Escondido, California, United States +90 more locations

COMPLETEDPhase 2144 miles

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

NCT04985916

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Lateral Canthal Lines, LCLCrow's Feet

Eirion Therapeutics Inc.280 participantsStarted Jul 2021

Scottsdale, Arizona, United States • San Diego, California, United States • Aventura, Florida, United States +16 more locations

COMPLETEDPhase 3164 miles

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

NCT02839330

This Phase 3 study evaluates the safety, immunogenicity and lot-to lot consistency of 3 lots of aH5N1c vaccine for pandemic avian influenza, in approximately 2394 healthy adults ≥18 years of age receiving the vaccine and 797 healthy adults receiving placebo. Subjects were randomized in a 3:1 ratio to receive either aH5N1c vaccine or saline placebo. Enrollment was stratified by age: 18 to \<65 years of age and ≥65 years of age, to allow adequate safety assessment of the entire age spectrum.

Avian Influenza

Seqirus3,196 participantsStarted Jul 2016

Huntsville, Alabama, United States • Chandler, Arizona, United States • Tempe, Arizona, United States +23 more locations

COMPLETEDPhase 2185 miles

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

NCT02799745

The primary purpose of this study was to compare the time to prostate cancer progression (pathological or therapeutic progression) between patients treated with enzalutamide versus patients undergoing active surveillance.

Prostate Cancer

Astellas Pharma Global Development, Inc.227 participantsStarted Jun 2016

Birmingham, Alabama, United States • Homewood, Alabama, United States • Tucson, Arizona, United States +51 more locations

COMPLETEDPhase 3185 miles

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

NCT00826280

Observe whether the administration of caffeine prior to regadenoson will affect the interpretation of test results in subjects with coronary artery disease (CAD) undergoing SPECT MPI

Coronary Artery Disease (CAD)

Astellas Pharma Inc347 participantsStarted Mar 2009

Birmingham, Alabama, United States • Huntsville, Alabama, United States • La Mesa, California, United States +22 more locations

COMPLETEDPhase 3185 miles

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

NCT03643965

The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal disease (ESRD), despite maximum tolerated treatment with renin-angiotensin system (RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).

Primary IgA Nephropathy

Calliditas Therapeutics AB365 participantsStarted Sep 2018

Birmingham, Alabama, United States • Tucson, Arizona, United States • Palo Alto, California, United States +139 more locations

Active Not RecruitingPhase 3202 miles

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

NCT04956692

The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and nonsquamous NSCLC by assessing the pharmacokinetics (PK), safety, and efficacy of pembrolizumab SC injection in combination with standard-of-care chemotherapy. The primary hypothesis of the study is Pembrolizumab SC is noninferior to pembrolizumab intravenous (IV) for Cycle 1 Area Under Curve (AUC) and Cycle 6 minimal concentration (Ctrough) at steady state. Participants who discontinue study treatment after receiving the first course of 35 administrations of pembrolizumab (approximately up to 2 years) for reasons other than disease progression or intolerability, may be eligible for a second course of pembrolizumab for up to approximately 1 additional year if they have experienced radiographic disease progression per RECIST 1.1 as assessed by BICR after stopping first course treatment.

Non-Small Cell Lung Cancer

Merck Sharp & Dohme LLC531 participantsStarted Aug 2021

Jonesboro, Arkansas, United States • Fullerton, California, United States • Los Alamitos, California, United States +123 more locations

COMPLETEDPhase 4216 miles

A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

NCT04502862

Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: * To evaluate the effect of dupilumab on additional participant reported sleep outcomes * To evaluate the effect of dupilumab on objective sleep assessment * To evaluate the effect of dupilumab on asthma symptoms * To evaluate the effect of dupilumab on lung function * To evaluate the safety of dupilumab

Sanofi202 participantsStarted Aug 2020

Bakersfield, California, United States • Culver City, California, United States • Los Angeles, California, United States +52 more locations

COMPLETED216 miles

Acorai Machine Learning Generalization (MLG) Study

NCT05835024

Acorai is developing a non-invasive monitoring system for the estimation of intracardiac hemodynamic parameters in patients with suspected or confirmed heart failure, and/or pulmonary hypertension, who require hemodynamic assessment. The device will be intended as a companion test or clinical decision support tool to be used and interpreted by qualified healthcare professionals to aid standard-of-care clinical assessment in identifying hemodynamic congestion and supporting personalized treatment of heart failure and pulmonary congestion. This study is part of the development of a non-invasive monitoring system for the estimation of intracardiac hemodynamic parameters. It will be conducted to collect the data needed to train the machine learning models retrospectively.

Acorai AB1,602 participantsStarted Aug 2023

Conway, Arkansas, United States • Little Rock, Arkansas, United States • Jacksonville, Florida, United States +15 more locations

Active Not RecruitingPhase 3221 miles

SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma

NCT04967521

This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib.

Advanced Dedifferentiated Liposarcoma

Sarcoma Alliance for Research through Collaboration108 participantsStarted Nov 2021

Aurora, Colorado, United States • Jacksonville, Florida, United States • Chicago, Illinois, United States +6 more locations

COMPLETEDPhase 1339 miles

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

NCT05751759

This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of mitiperstat.

Hepatic Impairment

AstraZeneca31 participantsStarted Mar 2023

Rialto, California, United States • Hialeah, Florida, United States • Orlando, Florida, United States +2 more locations

COMPLETEDNA543 miles

Audio Distraction for Traction Pin Placement

NCT05927480

Traction pin placement is a common way to temporarily manage femur fractures and unstable acetabular fractures while awaiting surgery. Skeletal traction is thought to reduce patient discomfort by improving fracture alignment as well as relaxing muscle spasm pain felt from the broken bone by stretching out the leg. Skeletal traction may also help prevent articular surface damage in the hip by decreasing joint pressure. Despite the benefits of skeletal traction, insertion of the traction pin can be a painful and unpleasant experience for the patient. Our study hopes to see if listening to music with headphones during insertion of the traction pin decrease patient pain and anxiety.

Lower Extremity Fracture

HealthPartners Institute54 participantsStarted Apr 2018

Miami, Florida, United States • Saint Paul, Minnesota, United States

COMPLETEDPhase 3727 miles

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

NCT02410772

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week, with direct observation of each dose by a health-care worker at least five of the seven days of each week. The standard six-month regimen is two months of isoniazid, rifampin, ethambutol, and pyrazinamide followed by four months of isoniazid and rifampin. The first short regimen is a single substitution of rifapentine for rifampin: two months of isoniazid, rifapentine, ethambutol, and pyrazinamide, followed by two months of isoniazid and rifapentine. The second short regimen is a double substitution of rifapentine for rifampin and moxifloxacin for ethambutol: two months of isoniazid, rifapentine, moxifloxacin, and pyrazinamide, followed by two months of isoniazid, rifapentine, and moxifloxacin. Target enrollment is 2500 participants. Each study participant will remain in the study for 18 months in order to include at least 12 months of evaluation of whether the participant's TB recurs.

Centers for Disease Control and Prevention2,516 participantsStarted Jan 2016

San Francisco, California, United States • New York, New York, United States • Fort Worth, Texas, United States +30 more locations

PreviousPage 228 of 722Next

in Georgia

Heart Diseasein Georgia